Prelude Therapeutics Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program

Reuters11-04

Prelude <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program

Prelude Therapeutics Inc. has announced an exclusive option agreement with Incyte for its mutant selective JAK2V617F JH2 inhibitor program, which is being developed for patients with myeloproliferative neoplasms (MPNs). Under the terms of the agreement, Incyte will pay Prelude $35 million upfront and make a $25 million equity investment by purchasing 6.25 million shares of Prelude non-voting common stock at $4.00 per share. Prelude will continue to develop the JAK2V617F program during the option period. If Incyte exercises its option to acquire the program, Prelude will receive an additional $100 million and may be eligible for up to $775 million in potential milestone payments, as well as royalties on net sales. If the option is exercised, Incyte will assume responsibility for the global development and commercialization of the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568054-en) on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580735820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580735820","market":"us","top_or_hot":-1,"title":"Prelude Therapeutics Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PRLD\">Prelude Therapeutics Inc</a>. has announced an exclusive option agreement with Incyte for its mutant selective JAK2V617F JH2 inhibitor program, which is being developed for patients with myeloproliferative neoplasms (MPNs). Under the terms of the agreement, Incyte will pay Prelude $35 million upfront and make a $25 million equity investment by purchasing 6.25 million shares of Prelude non-voting common stock at $4.00 per share. Prelude will continue to develop the JAK2V617F program during the option period. If Incyte exercises its option to acquire the program, Prelude will receive an additional $100 million and may be eligible for up to $775 million in potential milestone payments, as well as royalties on net sales. If the option is exercised, Incyte will assume responsibility for the global development and commercialization of the program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568054-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prelude Therapeutics Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrelude Therapeutics Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PRLD\">Prelude Therapeutics Inc</a>. has announced an exclusive option agreement with Incyte for its mutant selective JAK2V617F JH2 inhibitor program, which is being developed for patients with myeloproliferative neoplasms (MPNs). Under the terms of the agreement, Incyte will pay Prelude $35 million upfront and make a $25 million equity investment by purchasing 6.25 million shares of Prelude non-voting common stock at $4.00 per share. Prelude will continue to develop the JAK2V617F program during the option period. If Incyte exercises its option to acquire the program, Prelude will receive an additional $100 million and may be eligible for up to $775 million in potential milestone payments, as well as royalties on net sales. If the option is exercised, Incyte will assume responsibility for the global development and commercialization of the program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568054-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLbhhNtn:1","article_id":"2580735820","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580735820","pubTimestamp":1762257826,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Prelude Therapeutics Inc. has announced an exclusive option agreement with Incyte for its mutant selective JAK2V617F JH2 inhibitor program, which is being developed for patients with myeloproliferative neoplasms . Under the terms of the agreement, Incyte will pay Prelude $35 million upfront and make a $25 million equity investment by purchasing 6.25 million shares of Prelude non-voting common stock at $4.00 per share. Prelude will continue to develop the JAK2V617F program during the option period. If Incyte exercises its option to acquire the program, Prelude will receive an additional $100 million and may be eligible for up to $775 million in potential milestone payments, as well as royalties on net sales. If the option is exercised, Incyte will assume responsibility for the global development and commercialization of the program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","PRLD":"Prelude Therapeutics Inc","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","INCY":"因塞特医疗","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Prelude Therapeutics宣布与Incyte就JAK2V617F抑制剂项目达成独家选择权协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRLD":0.9,"INCY":0.9,"NDAQ":0.9},"content_text":"Prelude Therapeutics Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program\n    \n\nPrelude Therapeutics Inc. has announced an exclusive option agreement with Incyte for its mutant selective JAK2V617F JH2 inhibitor program, which is being developed for patients with myeloproliferative neoplasms (MPNs). Under the terms of the agreement, Incyte will pay Prelude $35 million upfront and make a $25 million equity investment by purchasing 6.25 million shares of Prelude non-voting common stock at $4.00 per share. Prelude will continue to develop the JAK2V617F program during the option period. If Incyte exercises its option to acquire the program, Prelude will receive an additional $100 million and may be eligible for up to $775 million in potential milestone payments, as well as royalties on net sales. If the option is exercised, Incyte will assume responsibility for the global development and commercialization of the program.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568054-en) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580735820","isCrawlerRequest":true}